Healthcare Industry News: Conceptus
News Release - May 5, 2006
Study Shows Essure(R) Procedure In-Office Placement SuccessMOUNTAIN VIEW, Calif.--(HSMN NewsFeed)--May 5, 2006--Conceptus, Inc. (Nasdaq:CPTS ), developer of the Essure® non-incisional permanent birth control system, today reports that a study from the Albert Einstein College of Medicine published in the March/April issue of the Journal of Minimally Invasive Gynecology demonstrates the Essure procedure can be safely and effectively performed in an office-based setting under local anesthesia.
"As this study shows, performing the Essure procedure in an office setting is easy and convenient for both the patient and the physician," said Mark Levie, M.D., of the Albert Einstein College of Medicine in Bronx, N.Y. "When permanent birth control is this simple and effective, it is easy to understand why the Essure procedure is becoming women's first choice in permanent birth control."
"We believe Essure permanent birth control will ultimately replace surgical sterilization as more women and physicians learn how easily and effectively the Essure procedure can be done in a doctor's office," said Mark Sieczkarek, president and chief executive of Conceptus, Inc., the company that pioneered the Essure procedure.
About the Essure® Procedure
The Essure procedure deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is able to return home about 45 minutes after the procedure is completed. There is a three-month waiting period after the procedure during which women must use another form of birth control. The Essure procedure is 99.80% effective after four years of follow-up. The Essure procedure has been demonstrated in a small portion of the women undergoing clinical studies to be 99.74% effective based on 5 years of follow-up. Five year follow-up of all patients in clinical trials is ongoing.
Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for over 1 million procedures annually.
Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available at www.Conceptus.com or by calling 1-877-ESSURE2.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements, the accuracy of which is necessarily subject to risks and uncertainties. Discussions regarding performance of Essure in the office setting, Essure replacing surgical sterilization and other matters discussed in this release, may differ significantly from the discussion of such matters in the forward-looking statements. Such differences may be based upon factors such as strategic planning decisions by management, re-allocation of internal resources, decisions by insurance companies, scientific advances by third parties and introduction of competitive products, as well as those factors set forth in the Company's most recent Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, and other filings with the Securities and Exchange Commission.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.